SESSION TITLE: Airways 4
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Revefenacin (pINN), a novel nebulized long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD), produces persistent and localized bronchodilation with limited systemic side effects. A 28-day study in participants with COPD demonstrated that the optimal benefit-to-risk ratio for revefenacin occurs at once-daily doses of 88 µg and 175 µg. To establish the long-term safety for this dose range, a 52-week phase 3 safety study in participants with COPD is in progress. The trial methodology and select characteristics of participants enrolled to-date are presented here.